This prospective study aims to investigate the potential of [18F]-fibroblast activation protein inhibitor ([18F]-FAPI)-04 PET/CT for evaluating suspected recurrent uterine malignancy after radical surgery, and prospectively compared with [18F]-Fluorodeoxyglucose ([18F]-FDG) PET/CT.

Read the full article on ejradiology.com